Press Releases – Cornerstone Pharmaceuticals

Press Releases

December 12, 2011 Cornerstone Pharmaceuticals’ cancer metabolism inhibitor, CPI-613, showing promise in Phase I trial for acute myeloid leukemia

October 26, 2011 Cornerstone Pharmaceuticals to present at the 9th Annual Discovery on Target Meetings in Boston

September 15, 2011 Cornerstone Pharmaceuticals publishes positive pre-clinical study results comparing its proprietary drug EmPAC™ to Taxol® in the Journal of Nanoscience and Nanotechnology

September 06, 2011 Cornerstone Pharmaceuticals announces FDA orphan drug designation of CPI-613 for patients with acute myeloid leukemia

July 25, 2011 Cornerstone Pharmaceuticals announces the Journal of Molecular Medicine’s publication of research showing selective inhibition of cancer cell energy metabolism with its novel lipoate derivative compounds

June 03, 2011 Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia

March 14, 2011 Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study

November 05, 2010 Cornerstone Pharmaceuticals Awarded $490K in Grants Under QTDP Program

October 11, 2010 Cornerstone Pharmaceuticals Presents Interim Phase I Data at the European Society of Medical Oncology Annual Conference

September 09, 2010 Dr. Robert Shorr, Leading Scientist in Cancer Metabolism, to Speak at Two Upcoming Pharmaceutical Conferences

Next »

inner-8